Myeloproliferative Disorders
Physician burnout is at a critical point. In this episode, Nicky speaks with Dr Alfred Atanda about why so many physicians are burning out and what can be done to change the trend. From personal experience to system-wide solutions, Dr Atanda shares valuable insights on improving physician well-being and building a more effective healthcare culture.
What if your medical degree could launch more than a clinical career? In this candid and compelling read, Dr Jon Edelson shares his lessons for early-career clinicians ready to think beyond the bedside and explore the business of medicine.
In this episode, we explore the future of continuing medical education (CME) with the team behind touchIME. Hannah Fisher and Matthew Goodwin share insights into global and US trends, the importance of patient inclusivity and how educational outcomes are evolving to better measure the direct impact of learning on clinical practice and patient care.
Nurses account for the largest group of professionals in the healthcare system and there are an estimated 29 million nurses worldwide (WHO, 2024). Nursing practice needs to be dynamic in order to respond to the changing needs of an aging population and ...
The American Society of Hematology (ASH) held its 66th Annual Meeting from 7–10 December 2024. Among the highlights of the meeting were six late-breaking abstracts that have the potential to influence how healthcare professionals approach a range of condition,s from introducing ...
The IMpactMF trial is a phase 1/1b study evaluating the addition of Imetelstat to ruxolitinib for myelofibrosis patients who show an inadequate response to ruxolitinib alone. By combining these therapies earlier in treatment, the study aims to assess safety, tolerability ...
Join editorial board member Dr John Mascarenhas (Icahn School of Medicine at Mount Sinai, New York, NY, USA) as he explores the potential of navtemadlin, an oral MDM2 inhibitor, as a treatment option for myelofibrosis. He discusses thehey take-aways from ...
Few alliances have impacted patient care as significantly as the Myeloproliferative Neoplasms Research Consortium (MPN-RC). Established in 2006, the MPN-RC is an international group dedicated to advancing research and developing innovative treatment strategies for myeloproliferative neoplasms (MPNs). In this episode, we speak with John Mascarenhas, MD, about the coalition's founding, operational mechanics and how their efforts have led to paradigm-shifting therapies in the field.
The phase II RESTORE trial evaluated elritercept (KER-050), an investigational treatment for myelofibrosis (MF) and ruxolitinib-associated cytopenias. Elritercept, targeting specific transforming growth factor-beta (TGF-β) ligands to improve haematopoiesis, was tested alone and in combination with ruxolitinib. In Part 1 (N=41), the trial assessed safety, tolerability, pharmacokinetics, and efficacy across doses (0.75-4.5 mg/kg). Results showed a 37% transfusion dependency among participants, with common adverse events including diarrhoea (22%), thrombocytopaenia (17%) and fatigue (15%). The recommended dose for Part 2 was 3.75 mg/kg, up-titrated to 5.0 mg/kg. Erythropoiesis improved in non-transfusion-dependent participants, with 54% showing increased hemoglobin (Hgb). Transfusion burden was reduced by ≥50% in 38% of transfusion-dependent participants. Additionally, spleen size and symptom scores decreased in 57% and 67% of evaluable participants, respectively. Elritercept showed potential to treat MF-related anemia, cytopenias, and splenomegaly, warranting further analysis.
The EHA 2024 congress has once again united top haematology experts from around the globe. This year's event featured plenty of innovations and developments, from novel therapies to cutting-edge genetic studies. In this article we provide an overview of the late-breaking abstracts presented at the meeting.
We’re looking forward to the EHA 2024 Hybrid Congress which is taking place in Madrid, between 13-16 June 2024. Promising attendees the opportunity to explore the latest advancements in haematology, including cutting-edge technologies, treatments, and products. The focus will encompass a ...
The phase II MANIFEST trial (NCT02158858) investigated the use of pelabresib combined with ruxolitinib for patients with myelofibrosis who are JAK inhibitor treatment-naïve. We caught up with Dr John Mascarenhas (Icahn School of Medicine at Mount Sinai, NY, USA), ...
Myelofibrosis is a complex haematological malignancy for which the current first-line treatment is Janus kinase inhibitors. touchHAEMATOLOGY caught up with one of our valued Editorial Board members, Dr John Mascarenhas (Icahn School of Medicine at Mount Sinai, NY, USA) to ...
The REVIVE study (NCT0405704) is a phase II study investigating the effect of rusfertide, a first-in-class hepcidin mimetic, on the control of erythrocytosis in patients with polycythaemia vera. touchHAEMATOLOGY caught up with Dr Marina Kremyanskaya (Icahn School of Medicine at ...
The REVIVE study (NCT0405704) is a phase II study investigating the effect of rusfertide, a first-in-class hepcidin mimetic, on the control of erythrocytosis in patients with polycythaemia vera. The unmet needs in the treatment of polycythaemia vera and the aims, ...
Momelotinib, a small-molecule oral inhibitor of the JAK1/JAK2 kinases was investigated in the phase 3 MOMENTUM study in patients with anaemic myelofibrosis (ClinicalTrials.gov Identifier: NCT04173494). touchHAEMATOLOGY were delighted to talk with Dr. Srdan Verstovsek (The University of Texas MD ...
Log into your Touch Account
Earn and track your CME credits on the go, save articles for later, and follow the latest congress coverage.
Sign up with an Email
Or use a .
This Functionality is for
Members Only
Explore the latest in medical education and stay current in your field. Create a free account to track your learning.
